Metformin Shows Promise for Knee Osteoarthritis Pain in Overweight Patients
Six-month trial finds diabetes drug metformin significantly reduces knee pain compared to placebo in people with osteoarthritis and excess weight.
Summary
A randomized clinical trial of 107 participants found that metformin, a common diabetes medication, significantly reduced knee pain in people with osteoarthritis who were overweight or obese. After six months, those taking 2000mg daily of metformin experienced an 11.4mm greater reduction in pain on a 100-point scale compared to placebo. The effect size was moderate (0.43) and statistically significant. This suggests metformin's anti-inflammatory properties may benefit joint health beyond diabetes management, offering a potential new treatment option for osteoarthritis pain.
Detailed Summary
Knee osteoarthritis affects millions worldwide, causing chronic pain and disability, particularly in people with excess weight. Current treatments focus mainly on pain management and weight loss, with limited options that address underlying inflammation. This study investigated whether metformin, known for its anti-inflammatory effects beyond diabetes treatment, could reduce osteoarthritis pain.
Researchers conducted a double-blind, placebo-controlled trial with 107 participants who had knee pain for at least six months, pain scores above 40mm on a 100mm scale, and BMI of 25 or higher. Participants were randomly assigned to receive either 2000mg daily metformin or identical placebo for six months, with follow-up conducted remotely via telemedicine.
The results showed metformin significantly outperformed placebo in reducing knee pain. The metformin group experienced a 31.3mm reduction in pain scores compared to 18.9mm in the placebo group—a between-group difference of 11.4mm. This represents a moderate effect size of 0.43 and was statistically significant. While not reaching the 15mm threshold considered clinically meaningful for individuals, the difference suggests meaningful population-level benefits.
The treatment was generally well-tolerated, with diarrhea and abdominal discomfort being the most common side effects, occurring slightly more frequently in the metformin group. The completion rate was high at 82%, indicating good acceptability of the intervention.
These findings suggest metformin's anti-inflammatory mechanisms may benefit joint health beyond glucose control, potentially offering a new therapeutic approach for osteoarthritis. However, the modest sample size means larger trials are needed to confirm these results and establish optimal dosing strategies before clinical implementation.
Key Findings
- Metformin reduced knee pain by 11.4mm more than placebo on 100mm pain scale
- Effect size was moderate (0.43) and statistically significant after 6 months
- 82% completion rate with generally well-tolerated side effects
- Benefits seen specifically in overweight/obese participants with osteoarthritis
- First randomized trial demonstrating metformin's potential for joint pain relief
Methodology
Double-blind, placebo-controlled randomized trial with 107 participants conducted via telemedicine. Participants had knee pain ≥6 months, pain scores >40mm, and BMI ≥25. Primary outcome was change in 100mm visual analog scale pain scores at 6 months.
Study Limitations
Modest sample size limits generalizability and requires confirmation in larger trials. Pain reduction didn't reach the 15mm individual clinical significance threshold. Study focused only on overweight/obese participants, limiting broader applicability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.